Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The Danish drugmaker’s arch-rival Eli Lilly & Co. has introduced another shot — Zepbound, also known as Mounjaro — that so ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

The Phase I trial - which had 72 participants - was designed to assess the safety and tolerability of the pill, as is common ...